Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy

Hao Ren, Jiahui Yong, Qingqing Yang, Zhen Yang, Zhangya Liu, Yan Xu, Hao Wang, Xing Jiang, Wenjun Miao, Xueming Li

School of Pharmaceutical Science, Nanjing Tech University, Nanjing 211816, China
School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China

Received 1 April 2021; received in revised form 28 April 2021; accepted 6 May 2021

Abstract Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death (ICD) to provoke a robust immune response for metastasis control. Here, a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumor penetration and synergistic therapy of starvation, chemodynamic (CDT) and...
Glucose oxidase; Tumor penetration; Synergistic therapy; ICD amplifier; Cancer immunotherapy; Metastasis inhibition

1. Introduction

Immune checkpoint blockade (ICB) based cancer immunotherapy is an attractive strategy for recurrent and metastasized cancer, due to the activation of anti-tumor immune response\(^1\)-\(^3\). Despite the remarkable progress in clinical cancer treatment, only a subset of cancer patients (5%-20%) show immune response with ICB therapy, because of the weak tumor immunogenicity and insufficient intratumoral infiltration of cytotoxic T lymphocytes (CTLs)\(^4\)-\(^5\). The introduction of immunogenic cell death (ICD) has been proved as a promising approach to reverse tumor immunosuppression\(^6\)-\(^8\). Dying tumor cells undergoing ICD can trigger a specific anti-tumor immune response by the release of tumor-associated antigens and damage-related molecular patterns (DAMPs), which promote the activation of dendritic cells (DCs) and recruit specific T cell engagement\(^9\)-\(^11\). Therefore, efficient approaches that destroy primary tumor and amplify ICD to provoke an immune response for eradication of metastasis are highly desirable.

Intracellular reactive oxygen species (ROS) can induce cellular oxidative damage that effectively induces ICD to provide anti-generative stimulus for the immune system\(^12\)-\(^14\). The Fenton reaction based chemodynamic therapy (CDT) can release iron (Fe) ions to catalyze the overexpression of hydrogen peroxide (H\(_2\)O\(_2\)). This results in the generation of hydroxyl radicals (·OH) in primary cancer treatment\(^15\)-\(^17\). The pronounced toxicity of ·OH can also trigger antigens release and regulates immunogenicity to promote maturation of DCs, thereby increasing the anti-tumor immune response\(^18\)-\(^20\). Thus, triggering sufficient ROS by CDT is suitable to amplify ICD and enhance ICB immunotherapy. However, the reaction kinetic of the Fenton reaction-based CDT is highly dependent on the performance of catalysts and reaction parameters\(^21\). The mildly acid (pH 5 to 6) and insufficient level of H\(_2\)O\(_2\) in tumor microenvironment may limit the CDT-induced ICD process for cancer immunotherapy\(^22\)-\(^24\).

To overcome these problems, glucose oxidase (GOx) has been proposed to increase intracellular H\(_2\)O\(_2\) concentration and decrease pH, thus accelerating the Fenton reaction to generate highly cytotoxic ·OH for enhanced CDT\(^25\),\(^26\). GOx is an endogenous oxides-reductase that selectively catalyze glucose to generate gluconic acid and H\(_2\)O\(_2\) in the presence of oxygen\(^27\),\(^28\). Due to Warburg effect, tumor cells consume more glucose for cancer growth. Therefore, the GOx could block glucose and oxygen supply to achieve tumor inhibition as starvation therapy\(^29\),\(^30\). In addition, Sun groups have found that the delivery of GOx with biomimetic nanoparticles could ablate tumors and facilitate DCs maturation to stimulate antitumor immune response by starvation therapy\(^31\),\(^32\). In the nearby of tumor blood vessels with oxygen supply, GOx-based starvation therapy could enhance CDT and the combination strategy could be used to amplify ICD to increase ICB immunotherapy in some degree. However, due to the increased tumor depth and oxygen consumption, hypoxia of tumor microenvironment was significantly enhanced and restricted the catalyze efficacy of GOx\(^33\)-\(^36\), resulting in unsatisfied primary tumor inhibition and an insufficient immune response. Therefore, we hypothesize that the combination of oxygen-independent photothermal therapy (PTT) would further eliminate residual cancer cells and induce sufficient ICD to provoke a robust anti-tumor immune response for ICB enhancement.

PTT can transfer light energy to heat and induce tumor cell apoptosis with hyperthermia for local cancer treatment\(^37\). Recent studies have indicated that PTT can promote ICD induction and the release of DAMPs to increase tumor immunogenicity, thereby enhancing the anti-tumor immune response\(^38\)-\(^40\). In addition, numerous pieces of evidence have also demonstrated the GOx activity can be strengthened along with increased temperature\(^41\). Thus, the photothermal effect of PTT could also enhance GOx-based starvation therapy and generate more H\(_2\)O\(_2\) to accelerate ·OH radicals for CDT enhancement. The combination therapy could effectively inhibit the progression of the primary tumor and induce strong anti-tumor response for metastatic tumor cells.

Unlike organic photosensitizers (indocyanine green, IR780, and others) easily to photo-quench, ultrasmall FeS nanodots can generate localized heat as PTT and also catalyze H\(_2\)O\(_2\) to produce ·OH as CDT\(^42\),\(^43\). They were synthesized with use human serum albumin (HSA) protein as template by a facile enzyme-biomimetic route at room temperature. Inspired by this mild biomimeralization method\(^44\),\(^45\), we utilized GOx instead of HSA to form FeS-GOx nanodots. It has been reported that the smaller nanodots could penetrate deeper at tumor site due to the reduced diffusional obstacle\(^46\)-\(^48\). The designed FeS-GOx nanodots could meet the demands of combined multi-therapy for primary tumor inhibition with higher deep penetration and induction of sufficient ICD for tumor immunotherapy enhancement. However, ultrasmall...
nanodots are quickly eliminated from body by the kidney, which results in short blood circulation time and reduced tumor accumulation\(^4\).

Considering this obstacle, the chemotherapy drug paclitaxel (PTX) as a model drug was introduced via hydrophobic interaction during the co-assembly of FeS-GOx nanodots to form larger FeS-GOx@PTX (denote as FGP; Fig. 1A). After intravenous injection, the larger FGP nanoparticles could effectively accumulate in tumors by the enhanced permeability and retention (EPR) effect. Subsequently, due to the acid tumor microenvironment, the FGP could disassemble to release PTX and smaller FeS-GOx nanodots for deeper penetration (Fig. 1B). The released PTX could induce tumor cell apoptosis for chemotherapy. In nearby of tumor blood vessels, GOx in FGP still maintained high enzymatic activity to catalyze glucose and produce \(\text{H}_2\text{O}_2\) with assistant of oxygen, shutting down nutrients supply as starvation therapy. The generation \(\text{H}_2\text{O}_2\) could accelerate Fenton reaction to produce more \(\cdot\text{OH}\) radicals for enhanced CDT (Fig. 1C). After near-infrared (NIR) laser irradiation (808 nm), the increased temperature of FGP-based PTT could strengthen GOx activity and result in starvation and CDT enhancement. In addition, with the increased tumor penetration of FeS-GOx nanodots, PTT could effectively kill deeper hypoxic tumors for primary tumor inhibition. So, the designed nanoparticles showed significant tumor inhibition with PTX-induced chemotherapy, PTT, starvation therapy and CDT. In addition, the synergistic therapy involving FGP amplified the induction of ICD to exposure calreticulin (CRT) expression on dying tumor cells, which induced DC maturation. Furthermore, in combination with the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) checkpoint blockade, FGP could significantly promote intratumoral infiltration of CTLs into distant tumors and inhibit growth (Fig. 1D). Taken together, the presently designed self-assembling FGP nano-reactor can effectively and synergistically eliminate primary tumor with deeper tumor penetration and can amplify ICD to active strong anti-tumor response for metastasis inhibition.

2. Materials and methods

2.1. Materials

Glucose oxidase (GOx) was purchased from Source Leaf Biotechnology Co., Ltd. (Shanghai, China). PTX and chlorin e6 were provided by Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). The fluorimetric hydrogen peroxide assay kit was provided by Sigma-Aldrich. (St. Louis, MO, USA). The cell counting kit-8 (CCK-8) and annexin V-fluorescein isothiocyanate, FITC apoptosis detection kit were obtained from Dojindo Laboratories (Kumamoto, Japan). HPF (2-[6-(4-hydroxy) xanthene-3-on-9-yl] benzoic acid) was obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti-mouse-CD11c-FITC, anti-mouse-CD80-APC, anti-mouse-CD86-PE, anti-mouse-CD3-APC, anti-mouse-CD8-PE were bought from BioLegend (San Diego, CA). HN-309, the fluorimetric hydrogen peroxide assay kit was provided by Sigma-Aldrich. (St. Louis, MO, USA). The cell counting kit-8 (CCK-8) and annexin V-fluorescein isothiocyanate, FITC apoptosis detection kit were obtained from Dojindo Laboratories (Kumamoto, Japan). HPF (2-[6-(4-hydroxy) xanthene-3-on-9-yl] benzoic acid) was obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti-mouse-CD11c-FITC, anti-mouse-CD80-APC, anti-mouse-CD86-PE, anti-mouse-CD3-APC, anti-mouse-CD8-PE were bought from BioLegend (San Diego, CA).

Figure 1  Schematic illustration of the synthetic process and therapeutic mechanism of the cascade bioreactor. (A) Construction process of the FGP bioreactor via enzyme-biomimetic route and drug-induced self-assembly method. (B) Illustration of FGP disassembly for deep tumor penetration. (C) Synergistic therapy of starvation therapy, CDT and PTT for primary tumor inhibition. (D) Synergistic therapy releases damage-related molecular patterns to amplify ICD for enhanced anti-tumor immunotherapy.
Subsequently, Na₂S solution (32 mmol/L) was added and samples were constantly stirred at 25 °C for 2 h. Finally, the FeS-GOx was obtained by dialysis for 12 h. The preparation procedure of FeS-HSA was similar as the synthesis method of FeS-GOx. In order to avoid the oxidizing of Fe²⁺, in the process of preparation, all addition chemicals were dissolved in degassed water and under the flow with N₂.

2.2. Synthesis of FeS-GOx nanodots

FeS-GOx nanodots were synthesized and simply modified by the previously described biomineralization method. Briefly, 20 mg GOx was dissolved in 2 mL deionized water, followed by the gradual addition of FeCl₂·4H₂O (30 mmol/L) with constant stirring. The pH was adjusted to 8.0 with NaOH (0.01 mol/L). Subsequently, Na₂S solution (32 mmol/L) was added and samples were constantly stirred at 25 °C for 2 h. Finally, the FeS-GOx was obtained by dialysis for 12 h. The preparation procedure of FeS-HSA was similar as the synthesis method of FeS-GOx. In order to avoid the oxidizing of Fe²⁺, in the process of preparation, all addition chemicals were dissolved in degassed water and under the flow with N₂.

2.3. Synthesis of FeS-GOx@PTX (FGP) and FeS-HSA@PTX (FHP)

FGP was constructed by the self-assembly of FeS-GOx induced by PTX as previously described. PTX in ethanol (10 mg/mL, 1 mL) ethanol solution was added to 2 mL of FeS-GOx solution and then mixed for 1 h to allow the formation of FGP nanoparticles. The supernatant was collected centrifugation at 10,000 rpm (GL-20G-II, Anting Scientific, Shanghai, China) centrifugation for 10 min and washed twice with water. Finally, excess PTX was removed by a 12-h dialysis. The obtained FGP was stored in 4 °C for further use. In order to evaluate the starvation therapy and H₂O₂ generation, FeS-HSA was instead of FeS-GOx to form FeS-HSA@PTX (denoted FHP). The preparation was similar as that of FGP.

2.4. Characterization of FGP

The concentration of GOx was determined using the BCA protein assay kit (Beyotime Biotechnology, Nanjing, China). The concentration of Fe was determined according to the ultraviolet—visible (UV—Vis) absorption spectrum using 2,2′-dipyridyl as a chromogenic agent. The concentration of PTX was analyzed by high-performance liquid chromatography (HPLC) (Shimadzu, Kyoto, Japan). The morphology and structure of nanoparticles were characterized by a transmission microscopy using a JEM-2100 microscope (JEOL, Tokyo, Japan). The stability of FGP nanoparticles suspended in PBS was determined by measuring the particles size and surface zeta potential by dynamic light scattering (DLS) using a Zetasizer Nano ZS-90 (Malvern Instruments, Malvern, UK). The disassembly of FGP was performed at pH 5.0 and pH 7.4 for 24 h. The size distribution of the disassembled nanoparticles was determined by DLS (Malvern). The chemical valences of the Fe elements were analyzed by X-ray photoelectron spectroscopy (XPS) using an ESCAlab250 electron spectrometer (Thermal Fisher Scientific, Waltham, MA, USA). The generation of hydroxyl free radicals (·OH) was recorded on an A300 electron spin resonance (ESR) spectrometer (Bruker, Leipzig, Germany) using 5,5-dimethyl-1-pyrroline N-oxide (DMPO) as the spin trapping agent.

2.5. Catalytic activity of FGP

Catalytic activity of FGP was mainly evaluated by pH variation, oxygen consumption and H₂O₂ generation. Briefly, a series of FGP concentrations were added to 3 mL phosphate buffer. Following the addition with glucose (2 mg/mL), the variation in the oxygen concentration variation was detected by a real-time portable dissolved oxygen analyzer (Leici Co., Ltd., JPB-607 A, Shanghai, China) and the pH variation was immediately monitored by a pH meter (Leici Co., Ltd., PHSJ-5, Shanghai, China). Additionally, the generation of H₂O₂ was determined by Fluorometric Hydrogen Peroxide Assay Kit according to the standard protocols. To demonstrate the influence of temperature on enzymatic activity, 10 μg GOx (0.2 mg/mL, 50 μL) was added into a glucose solution (9 mg/mL), then the reaction was processed under different temperature conditions from 25 to 70 °C for 15 min. The pH changes of the mixture of FGP (200 μg/mL) and glucose (9 mg/mL) under different temperature at 25, 37, 42, and 47 °C was detected.

2.6. In vitro PTX release study

FGP samples (2 mL) containing 1 mg/mL PTX were dialyzed against 40 mL PBS (pH = 7.4 or pH = 5.8) containing 0.2% (w/v) Tween-80 at 37 °C with constant shaking at 100 rpm. At specific time intervals, 2 mL of the dialysis solution was removed and an equal volume of fresh PBS was added at the same time. And then, the concentration of PTX was analyzed by HPLC (Shimadzu) using a water/acetonitrile mixture (45/55, v/v).

2.7. In vitro photothermal study

In order to evaluate the photothermal performance of FGP, 0.2 mL FGP samples containing 200, 300 or 600 μg/mL Fe were NIR irradiated at 808 nm using a laser operating (Leilan Co., Ltd., Wuhan, China) at a power density of 1.6 W/cm². The temperature was recorded every 1 min by a thermometer. The photo-stability of FGP was measured during five cycles of irradiation (5 min for each cycle).

2.8. Detection of ·OH generation

Methylene blue (MB) decolorization was used to determine ·OH generation. MB (10 μg/mL) was added into FGP solutions containing 30 μg/mL Fe and 300 μg/mL GOx, followed with addition of glucose (10 mg/mL). The absorption changes at 665 nm were determined at different times using a model UV-2450 UV—Vis spectrophotometer (Shimadzu, Kyoto, Japan). The same method was also used to evaluate ·OH generation of FGP (100 μg/mL) in buffers with a pH 5.0, 6.5 or 7.4. In addition, the temperature of the water bath that was used was increased to 42 °C to simulate the photothermal effect of FGP with NIR laser to assess the enhanced generation ·OH.

3.3′,5,5′-Tetramethylbenzidine (TMB) can be oxidized by ·OH to form the blue oxide of TMB (oxTMB). Based on this observation, the TMB chromogenic method was also used for ·OH detection.
The in vitro cytotoxicity

The in vitro cancer cell cytotoxicity induced by the Fenton reaction, starvation therapy, and the combination therapy with FGP was evaluated in 4T1 breast cancer tumor cells. In brief, 4T1 cells were seeded at a density of 8000 cells per well in 96-well plates and incubated overnight. The cells were untreated (PBS added) or treated with different concentrations of FGP for 4 h in DMEM medium with or without glucose. To create a hypoxic condition, the cells were incubated with fresh medium containing FGP (0.015 mg/mL GOx and Fe concentration of 100 and 200 μg/mL) for 2 h. The cells were detached, collected and washed with PBS. Finally, the fluorescence images of cells were obtained by a fluorescence microscope (Nikon). The mean fluorescence intensity of the cells was calculated based on Image J software (NIH, Bethesda, MD, USA).

2.11. Intracellular generation of ROS and ·OH

The intracellular generation of ROS and ·OH was measured by flow cytometry (ACEA Biosciences). The fluorescence detection probes carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H₂DCFDA) with excitation (Ex) and emission (Em) wavelengths of 495 and 525 nm, respectively, and HPF (Ex/Em = 490/515 nm) were applied to respectively evaluate the intracellular ROS and ·OH level in 4T1 tumor cells, respectively. In brief, 4T1 cells were treated with FGP or FHP (with an equivalent Fe concentration of 180 μg/mL) for 2 h. The cells were rinsed and stained with carboxy-H₂DCFDA (20 μmol/L in serum-free medium) and HPF (10 μmol/L) at 37 °C for 30 min. The cells were then fixed in 4% formaldehyde polymer and labeled with 4',6-diamidino-2-phenylindole (DAPI, 1 μg/mL), and washed twice with PBS. Finally, the fluorescence images of cells were captured by a fluorescence microscope and the mean fluorescence was calculated by Image J software (NIH, Bethesda, MD, USA). The ROS generation was also similarly evaluated by flow cytometry (ACEA Biosciences) using 4T1 cells seeded in six-well plates (1 × 10⁶ cells per well) and centrifuged when required, and suspended in PBS for analysis.

2.12. In vitro detection of H₂O₂

The generation of H₂O₂ in vitro was measured by the Fluorimetric Hydrogen Peroxide Assay Kit according to the standard protocols. The 4T1 tumor cells (8000 per well) were permitted to adhere overnight. After 2-h treatment with RPMI 1640 medium containing various concentrations of FGP (GOx 0.02, 0.05, or 0.1 mg/mL), the cells were washed twice with PBS and stained with Fluorimetric Hydrogen Peroxide Assay Kit for 15 min. Finally, fluorescence (Ex/Em = 540/590 nm) was detected by the VICTOR Nivo multimode microplate reader (PerkinElmer, Waltham, MA, USA).

2.13. In vitro detection of CRT expression

To evaluate the ICD amplifier, CRT expression on the surface of 4T1 tumor cells was determined by immunofluorescence staining. The 4T1 cells were incubated in six-well plates at a density of 1 × 10⁶ per well and after incubation for 24 h. The cells were treated with PBS, FGP and FHP (GOx 100 μg/mL, Fe 180 μg/mL) for 3 h. After NIR irradiation (808 nm, 1.6 W/cm², 3 min), the cells were rinsed, incubated with Alexa Fluor 488-conjugated secondary antibody according to the standard protocols. Fluorescence images were captured by a fluorescence microscope (Nikon). The mean fluorescence intensity was calculated based on Image J software (NIH).

2.14. In vitro determination of HMGB-1 and ATP

The cellular high mobility group box 1 (HMGB-1) was evaluated by a HMGB-1 ELISA kits according to the manufacture's
protocol. Briefly, 4T1 cells were seeded in 12-well plates at a density of $5 \times 10^5$ cells per well and incubated overnight. After treatment with FHP and FGP (GOx 50 $\mu$g/mL, Fe 180 $\mu$g/mL) for 3 h, the 4T1 cells were irradiated with an 808 nm laser (1.6 W/cm$^2$) for 3 min. Finally, the supernatant was centrifuged for 3 h, the 4T1 cells were irradiated with an 808 nm laser in the extracellular environment was determined by bioluminescence assays. The 4T1 cells ($1 \times 10^6$ per well) were seeded in six-well plates and incubated for 24 h in advance. Then, the cells were treated with PBS, FHP and FGP (GOx 25 $\mu$g/mL, Fe 180 $\mu$g/mL) for 3 h. After NIR irradiation (808 nm, 1.6 W/cm$^2$, 3 min), the cell supernatant was collected and centrifuged at 2500 rpm (LGJ-10C, Foring technology, Beijing, China) for 5 min. Then, the extra- cellular ATP was determined using ATP assay kit (Beyotime, Nanjing, China) and light emission was measured with Multi- mode board reader (VICTOR NIVO™).

2.15. Intracellular Fe$^{2+}$ determination
The intracellular Fe$^{2+}$ was evaluated by FerroOrange (Ex/Em = 490/515 nm) (Dojindo, Tokyo, Japan), which is a novel fluorescent probe that enables live-cell fluorescent imaging of Fe$^{2+}$. Briefly, 4T1 cells were seeded in 12-well plates at a density of $5 \times 10^5$ cells per well and incubated overnight. After incubation with FHP and FGP (GOx 25 $\mu$g/mL, Fe 180 $\mu$g/mL) for 3 h, the 4T1 cells were labeled with FerroOrange (1 $\mu$mol/L) working solution for another 30 min. Finally, the fluorescence of Fe$^{2+}$ in 4T1 cells was observed under a confocal fluorescence microscope (OLYMPUS, FV1000, Tokyo, Japan).

2.16. Animals and tumor model
Six-week-old female BALB/c mice were provided by Yangzhou University Medical Center (Yangzhou, China). All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Nanjing Tech University. All experimental procedures were executed according to the protocols approved by the Animal Ethics Committee of Jiangsu University Medical Center (Yangzhou, China). The mice were intravenously injected with saline, FHP and FGP (containing GOx 300 $\mu$g/mL, and Fe 500 $\mu$g/mL) and NIR laser irradiated (808 nm, 1.6 W/cm$^2$). The increased temperature of mice were captured by an IR imaging device (FLIR ONE Gen3 IR imaging device (FLIR Systems, Arlington, VA, USA) every 1 min. Temperature changes were recorded using a visual IR thermometer (FLIR Tools).

2.20. In vivo anti-tumor efficacy
When the tumor size reached about 100 mm$^3$, 36 tumor-bearing mice were randomly divided into six groups ($n = 6$ per group). The mice were intravenously injected with 200 $\mu$L of saline (groups 1 and 2), FHP (HSA 300 $\mu$g/mL, Fe 500 $\mu$g/mL; groups 3 and 4), and FGP (GOx 300 $\mu$g/mL, Fe 500 $\mu$g/mL; groups 5 and 6). Groups 1, 3, and 5 were not treated any further. Groups 2, 4, and 6 additionally received NIR by irradiating the tumor region with 808 nm (1.6 W/cm$^2$) for 3 min 24-h post-injection. Tumor volumes and body weights of the mice were simultaneously recorded every 2 days. The tumor volume was calculated as Eq. (1):

Tumor volume = (Width × Width × Length)/2

On Day 15, the tumors were collected from anesthetized mice and each wound was carefully sutured. Each tumor was weighed. After 3 weeks, the mice were sacrificed and the lungs of each group were collected and rinsed with PBS. The metastatic nodules on the pulmonary tissues were counted, and the lung sections were stained by Hematoxylin and Eosin (H&E) to further evaluate the metastatic foci. To evaluate the therapeutic efficacy of the different treated groups, the tumor-bearing mice were treated as described about and tumors were removed on Day 4 for hematoxylin and eosin (H&E) and Ki67 staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis.

2.21. ICD amplifier to enhance anti-CTLA4 immunotherapy
Mice bearing both left and right 4T1 tumors were used to evaluate the therapeutic efficacy of FGP combined with anti-CTLA4 immunotherapy. To establish the bilateral tumor model, the right flank (primary tumor) was injected with $1 \times 10^5$ cells and the left
flank (distant tumor) was injected with $2 \times 10^5$ cells. After inoculation about 7 days, the primary tumor reached nearly 100 mm$^3$. The mice were divided into five groups ($n = 6$ per group). The groups received saline (group 1), saline + anti-CTLA4 (group 2), FHP (HSA 300 $\mu$g/mL, Fe 500 $\mu$g/mL) + anti-CTLA4 (group 3), FGP (GOx 300 $\mu$g/mL, Fe 500 $\mu$g/mL) + anti-CTLA4 (group 4), and FGP + anti-CTLA4 (group 5). Groups 2, 3, and 5 additional were treated using NIR laser irradiation (808 nm, 1.6 W/cm$^2$) for 1 min and irradiated for 3 times (total 3 min), after 24-post injection. The interval between irradiations was 1 min to avoid increased temperature of single NIR laser irradiation. The anti-CTLA4 antibody was intravenously injected about 20 $\mu$L per mouse on Days 2, 5 and 8. The primary and distant tumor growth curves were obtained within 14 days.

For CRT expression and DC maturation in vivo, the tumor-draining lymph nodes (TDLN) and primary tumors were collected on Day 3 after the various treatments as described above. Frozen sections of primary tumors in each group were stained with CRT primary antibody and fluorochrome-conjugated secondary antibody according to the standard protocols. They were also stained with DAPI. Finally, the fluorescence images were captured by fluorescence microscope. The TDNL were ground and filtered to obtain single cell suspensions. The cells were stained with FITC anti-mouse CD11c (Clone: N418, Catalog: 117,305), PE anti-mouse CD86 (Clone: GL-1, Catalog: 105,008) and APC anti-mouse CD80 (Clone: 16-10A1, Catalog: 104,714) antibodies (all from BioLegend, San Diego, CA, USA). The samples were examined by flow cytometry.

For the evaluation of T cell infiltration, distant tumors were collected on Day 7 after the different treatments. They were digested with an enzyme mixture and filtered to prepare single cell suspension. Then the cells were stained with APC anti-mouse CD3 (Clone: 17-A2, Catalog: 100,235; BioLegend) and PE anti-mouse CD8 (Clone: 53-6.7, Catalog: 100,708; BioLegend) antibodies and collected for flow cytometry analysis. The immunofluorescence staining of CD8 and IFN-γ was also performed in distant tumors. Images were captured by fluorescence microscopy (Nikon).

### 2.22. Biosafety of FGP in vivo

Six female ICR mice were randomly assigned to two groups for assessment of the blood glucose levels assessment ($n = 3$ per group). The mice were intravenously injected with saline and FGP (GOx 300 $\mu$g/mL, Fe 500 $\mu$g/mL). A commercial glucometer blood was employed for the detection of glucose in mice blood samples at the predesigned time interval (0, 1, 2, 3, 6, 9, 12 and 24 h) post injection.

The blood biochemical analyses of ALT, AST, ALP, BUN, and CREA were performed to indicate the biosafety of FGP. After treatment with FGP and saline for Days 1, 3, and 7, the whole blood was collected from these four groups and centrifuged, and the supernatant were analyzed. Organs were harvested and H&E staining was performed.

### 3. Results and discussion

#### 3.1. Preparation and characterization of FGP

FGP nanoparticles were prepared by two steps via the hydrophobic drug-induced assembly method. First, ultrasmall FeS-GOx nanodots were synthesized by a facile enzyme-biomimetic route at room temperature. And then, a clinically used paclitaxel chemotherapeutic drug was introduced to the co-assembled FeS-GOx nanodots by hydrophobic interaction to form larger FGP nanoparticles. As evident in the representative TEM images in Fig. 2A and B, the synthesized FeS-GOx nanodots and FGP nanoparticles were uniform in size with the average diameter of 12 and 160 nm, respectively. These measurements were similar to the dimensions obtained by dynamic light scattering (DLS) (Fig. 2C). These results indicated the successful assembly of FeS-GOx nanodots to FGP mediated by PTX. In addition, in this study, PTX was used as model drug to induce the self-assembly of FeS-GOx. The other anti-inflammatory drugs or photosensitizes (such as curcumin, pipery and IR780) could also induce ultrasmall FeS-GOx nanodots to form larger nanoparticles.

As shown in Fig. 2F, the X-ray diffraction patterns (XRD) of FGP and GOx showed no crystalline peaks, indicating that the embedded FeS nanodots were in an amorphous phase. Energy-dispersive spectrometry (EDS) and X-ray photoelectron spectroscopy (XPS) were performed to confirm the structure and components of FGP. The FGP nanoparticles were confirmed to contain the C, O, Fe and S elements (Fig. 2G). In addition, the Fe and S elemental composition in FGP was further confirmed by scanning electron microscopy (SEM)-EDS mapping (Fig. 2H). XPS of FeS-GOx nanodots revealed a binding energy of 710.8 eV as characteristic peak of FeS, with Fe (2p1/2) binding energy of 724.5 eV (Fig. 2I). The concentration of Fe$^{2+}$ was determined by 2,2'-dipyridyl in a standard manner (Supporting Information Fig. S3) and the calculated FGP loading efficacy was 5.6%. The PTX and GOx contents in these nanoparticles were 45.8% and 32.5%, as determined by HPLC (Supporting Information Fig. S4) and BCA protein assay kit, respectively. These results indicated that FGP nanoparticles were successfully prepared by biominalization and the drug-induced self-assembly method.

#### 3.2. Fenton reaction properties and PTT of FGP

GOx is a catalyst that facilitates the reaction of glucose and oxygen to produce H$_2$O$_2$ and gluconic acid. The oxygen consumption, H$_2$O$_2$ generation and pH decreased were monitored over time to evaluate the enzyme activities of FGP nanoparticles. As shown in Fig. 3A, rapid oxygen consumption was observed after with addition of glucose due to the catalytic activity of GOx in FGP. In addition, a significant pH decline from 7.2 to 3.0 was observed after the treatment of FGP with glucose for 90 min. The rate of decline of pH was related to the concentration of GOx (Fig. 3B). With oxygen consumption, H$_2$O$_2$ was generated as determined by a fluorometric hydrogen peroxide assay. As shown in Fig. 3C, the concentration of H$_2$O$_2$ in FGP increased after addition of glucose. Interestingly, compared to the same concentration of free GOx (Supporting Information Fig. S5), H$_2$O$_2$ generation in FGP decreased after adding glucose for 15 min, which indicated that the H$_2$O$_2$ produced from the catalytic oxidation was consumed in Fenton reaction of FGP.

To confirm the -OH generation, TMB oxidization and MB degradation of FGP with glucose were determined by examination
of the UV–Vis spectra. In the presence of OH, colorless TMB is oxidized to blue oxide of TMB, with a major absorbance peak at 652 nm. As shown in Fig. 3D, a blue-colored solution with a unique absorption peak was obtained after treatment of FGP with a TMB-glucose solution. In addition, the degradation of MB over time is displayed in Fig. 3E. After 30 min, MB had almost completely degraded, confirming the production of OH by FGP and glucose. MB degradation was enhanced by the increased concentration of FGP due to the generation of more H2O2 (Supporting Information Fig. S6). On the basis of the above results, electron spin resonance (ESR) using DMPO was further performed to detect OH production capacity of FGP (Fig. 3F). A strong ESR signal of radical spin adduct was observed after mixing FGP with glucose. The other groups (glucose, FGP and FHP) did not show any significant spectra. These results confirmed that FGP could catalyze glucose to generate H2O2 and OH for starvation and chemodynamic therapy.

Taking hypoxia in deeper regions of a tumor into consideration, MB was used as an -OH-specific indicator to evaluate the performance of the Fenton reaction of FGP nanoparticles under the hypoxic or normal condition. The hypoxic condition was created by continuously pump nitrogen into solution. Compared with FGP in the hypoxic condition, the MB absorbance of FGP in the normal condition was significantly decreased, indicating that hypoxia limited the OH generation of FGP (Fig. 3G). This may be because in the absence of oxygen, the enzyme catalytic activity could inhibit the oxidation of glucose to generate H2O2 and the Fenton reaction production of OH. These findings indicated that single chemodynamic therapy of FGP would not be a better treatment in cancer.

Due to the broad absorbance of FGP, the PTT effect was evaluated using 808 nm laser as the light source. As shown in Fig. 3H, the temperature of FGP at different concentrations was significantly increased under laser irradiation (808 nm, 1.8 W/cm², 5 min). The temperature of FGP increased approximately 21 °C at the Fe concentration of 600 mg/mL. Furthermore, this photothermal conversion effect was very stable during five cycles of irradiation (each cycle comprised 5 min irradiation with an intervening 5 min), as shown in Supporting Information Fig. S7. It has been reported that the PTT could enhance GOx activity and produce more H2O2 for the Fenton reaction. As shown in Supporting Information Figs. S8 and S9, with a temperature increase from 30 to 55 °C, the H2O2 was significantly increased, and pH decreased more quickly. These results indicated that the PTT effect of FGP could enhance GOx activity. Thus, the efficiency of OH production was then examined to understand the promoting role of PTT. The MB decoloration experiment clearly demonstrated that the heat generated from the photothermal conversion could accelerate and improve OH generation (Fig. 3I). This was because the increased temperature simultaneously promoted the activity of GOx. The collective results confirmed that FGP could...
accelerate ·OH by PTT and the benefit of the combined PTT, amplified chemodynamic and starvation therapy for cancer treatment.

3.3. Fenton reaction of FGP in tumor cells

To better evaluate the Fenton reaction of FGP for cancer cell treatment, C6-labeled FGP was incubated with 4T1 cells for 0.5, 1 and 2 h, and the cellular uptake was studied by flow cytometry analysis. As observed in Supporting Information Fig. S10, the amount of FGP at the cellular level increased significantly with time. As confirmed above, GOx was the key point in FGP to catalyze glucose to produce H$_2$O$_2$ and ·OH for starvation and chemodynamic therapy. Cellular cytotoxicity was evaluated in 4T1 cells by the CCK-8 assay. As shown in Fig. 4A, treatment of FHP with glucose and FGP treatment without glucose were less toxic to cancer cells. In the case of the same concentration of GOx and glucose, FGP was significantly toxic to normoxic cancer cells compared to hypoxic cancer cells. These results indicated that GOx in FGP could consume glucose with oxygen to generate H$_2$O$_2$ and induce the Fenton reaction, thus killing cancer cells. To confirm the mechanism of cytotoxicity in 4T1 cells, the generated ROS were stained with the DCFH-DA fluorescence probe. As revealed in Fig. 4B, cells treated with FGP showed slight green fluorescence of DCFH compared to cells treated with FHP. The findings suggested that GOx could effectively catalyze the glucose into H$_2$O$_2$ and generate ·OH. Weak fluorescence was also observed in 4T1 cells treated with FHP, probably due to the endogenous H$_2$O$_2$ of tumor cells and the slight amount of ·OH produced by endogenous H$_2$O$_2$ in the Fenton reaction. The trends observed after DCF staining were further validated by quantitative flow cytometric analysis (Fig. 4C).

The cellular generation of H$_2$O$_2$ in 4T1 cells was determined by a fluorimetric hydrogen peroxide assay after incubation with different concentrations of FGP. As showed in Fig. 4D and Supporting Information Fig. S11, compared with the control group, the H$_2$O$_2$ generation in the FGP groups was significantly increased and a similar decreasing trend was observed in FGP groups after incubation for approximately 30 min. The level of H$_2$O$_2$ initially increased and then decreased along with the catalytic oxidation and Fenton reaction.

To further confirm the ·OH generation of the Fenton reaction of FGP, the HPF commercial ·OH-specific fluorescent probe was applied to distinguish ·OH from H$_2$O$_2$ produced by GOx and to determine the intracellular ·OH (Fig. 4E and F). Compared to FHP treatment, cells treated with FGP showed slightly increased (2.6-fold) green fluorescence of HPF. This may be because FGP could speed up the oxidation of GOx to furnish excess H$_2$O$_2$ and generate more ·OH radicals. As known to us, Fe$^{2+}$ was the key point for Fenton reaction. So, the intracellular Fe$^{2+}$ was evaluated
by FerroOrange (Ex/Em = 490/515 nm), which is a novel fluorescent probe that enables live-cell fluorescent imaging of intracellular Fe$^{2+}$. As shown in Supporting Information Fig. S12, after incubation of FGP in 4T1 cells, the red fluorescence of Fe$^{2+}$ was brighter than that in control group, nearly 10-times. The control group also showed slight fluorescence due to the metabolism of iron in 4T1 cells. These results indicated that FGP nanoparticles could provide Fe$^{2+}$ to increase Fenton reaction for CDT treatment.

To accurately analyzed the viability of treated 4T1 cells, Annexin V-FITC and PI staining assay was performed by flow cytometric analysis (Fig. 4G and Supporting Information Fig. S13). The proportion of apoptosis cells was 44.37% after treatment with FGP and glucose, indicating that GOx-based starvation therapy and Fenton reaction could lead to apoptosis of cancer cells. The results were also potential confirmation that the single treatment of FGP might not achieve better cancer treatment in the deeper hypoxic regions of tumors. Rather, FGP should be combined with PTT for cancer treatment.

3.4. In vitro combination therapy of FGP to increase CRT expression

Due to the increased temperature induced by the photothermal effect of FGP, the synergistic effect of starvation therapy, chemodynamic therapy and PTT was evaluated in 4T1 tumor cells in the presence or absence of NIR laser by CCK-8 assays. As demonstrated in Fig. 5A, compared with FHP treatment, a gradual decrease in the cellular viability of 4T1 cells was observed with increased concentration of GOx in FGP without laser irradiation. This may have reflected the efficacy of starvation and Fenton reaction. After NIR laser irradiation, both FHP and FGP showed increased cytotoxicity due to the photothermal effect of the Fe$^{2+}$-GOx nanodots. To further evaluate the combination therapy of FGP, 4T1 tumor cells were stained with calcine-AM (green fluorescence) and PI (red fluorescence) to visualize live and dead cells, respectively. As illustrated in Fig. 5B and 4T1 cells that were not irradiated displayed higher red fluorescence when treated with FGP as compared to treatment with FHP. Under laser irradiation, the red fluorescence was increased in nearly 80% of cells, similar as the results determined by CCK-8 assays. In addition, Annexin V-FITC and PI staining assay was performed by flow cytometric analysis to confirm the therapeutic efficacy. As shown in Fig. 5C and Supporting Information Fig. S14, the proportion of apoptotic cells in the FGP treated group reached nearly 80%, which was 2-fold higher than that of the FHP treated group. The collective results indicated better therapeutic efficacy of FGP in vitro, due to the combination therapy of starvation, chemodynamic, and PTT.
The photothermal effect and ROS generation reportedly enhance immunotherapy-related ICD, especially increased calreticulin (CRT) exposure on the surface of dying tumor cells\(^5\). As described above, FGP showed better synergistic therapeutic efficacy of cancer cells in vitro. CRT expression was explored by staining with CRT primary anti-body and Cy3-conjugated secondary antibody. The resulting green fluorescence was captured by CLSM. As shown in Fig. 5D and E, 4T1 cells treated with FGP and laser irradiated showed brighter green fluorescence (mean fluorescence intensity [MFI] of 179.3), which was nearly 4.1-fold higher than that of cells treated with FGP but without laser irradiation (MFI of 43.7). In addition, upon laser irradiation, the FHP group displayed more green fluorescence than that of cells treated with FGP and FHP but not laser irradiated (MFI of 58.2 vs. 22.6). These results indicated that combination therapy could increase CRT exposure of 4T1 cells.

As known to us, HMGB-1 released from dying cells could induce inflammation to attract immune cells and mature DC cells. So, the extracellular HMGB-1 was determined to evaluate ICD expression after different treatments in 4T1 cells. As shown in Supporting Information Fig. S15, after treated with FHP and FGP without NIR illumination, HMGB-1 was significantly increased due to the generation of \(\cdot\text{OH}\). Furthermore, because of GOx catalyzed to increase H\(_2\)O\(_2\) generation and induce more ROS, FGP showed

![Figure 5](image-url)
significantly increased translocation of HMGB-1 from nuclear to extracellular medium, compared with FHP. After NIR laser irradiation, extracellular HMGB-1 of 4T1 cells in FGP was highest compared with other treatments. These results indicated that the designed FGP nanoparticles could release HMGB-1 from cancer cells and induce ICD to active immune response. In addition, the release of ATP in different treatments were also determined by bioluminescence assays. As shown in Supporting Information Fig. S16, compared with control groups, FHP and FGP with or without laser irradiation released more ATP to extracellular medium to active immune response, which is similar as the results of CRT expression. But the release of ATP in FGP (with or without laser) was lower than that in FHP group. This may be due to the catalyze property of GOx in FGP nanoparticles to consume glucose and decrease ATP generation in cancer cells as starvation therapy. But taking all the results of CRT expression, the release of ATP and HMGB-1 into consideration, FGP with NIR laser irradiation could amplify ICD to induce anti-tumor immune response.

### 3.5. Disassembly of FGP for tumor penetration

Previous studies reported that PTX induced self-assembly of nanoparticles and the release of PTX disassembled smaller nanodots.50 The scheme showed the dissociation behavior of FGP, as illustrated in Fig. 6A. The release behavior of PTX from FGP at 37 °C was determined by HPLC. Approximately 43.6% of PTX was released at pH 5.5 within 48 h, was nearly 2-fold higher than that occurring at pH 7.4, indicating a pH-responsive release property of PTX (Fig. 6B). To confirm the pH-responsive degradability of the FGP, the particle size distribution of FGP was also determined at different PBS buffers (pH 7.4 and pH 5.0). After 24 h, no significant change of FGP was evident at pH 7.4, while smaller nanodots of approximately 30 nm were observed at pH 5.0 (Fig. 6C). These results indicated that the acid tumor microenvironment could rapidly induce FGP disassembly to release PTX and smaller FeS nanodots.

As the smaller nanodots could penetrate deeper into tumors, we were interested in evaluating whether the disassembly of FGP could promote tumor penetration in vitro. Ce6-labeled FGP nanoparticles were incubated with 4T1 multicellular tumor spheroids (MCTS) in culture medium with a pH of 7.4 or pH 6.0 cell for 24 h. MCTS incubated with FGP at pH 6.0 displayed green fluorescence only at the margin regions of the 60 μm-thick sections, due to the limited penetration of the larger FGP. Taken together, the collective findings indicate that FGP could quickly disassemble to smaller FeS nanodots in acid tumor microenvironment and effectively penetrate into deep tumor.
The smaller FeS-GOx nanodots could enhance tumor penetration, but could be easily cleared out, leading to reduced tumor accumulation, due to the short circulation time. Self-assembly FGP would maintain a relative larger size in blood and accumulate in tumor via EPR effect. Thus, the in vivo comparison of the tumor accumulation of Ce6-labeled FeS-GOx and FGP was conducted by near-infrared fluorescence (NIRF) imaging in vivo. As shown in Supporting Information Fig. S17, after intravenous injection of FGP, the red fluorescence of Ce6-labeled FGP was observed in all tumors frozen slice. Furthermore, the fluorescence of Ce6 was also observed in tumor cells, which indicated that nanoparticles could access into cancer cells, which is possible to induce ICD after treatment of FGP. The concentration of Fe$^{2+}$ in tumor was also evaluated by corresponding Iron assay kits (Dojindo), after intravenous injection of saline and FGP. As shown in Supporting Information Fig. S18, the concentration of Fe$^{2+}$ was higher than that in saline group. These results further indicated that FGP could accumulate and enhance tumor penetration at tumor site. The collective data indicated that the large size of FGP nanoparticles could enhance accumulation at tumors with subsequent disassemble to smaller nanodots allowing deeper penetration.

3.6. In vivo anti-tumor and anti-metastatic effect of FGP

FGP along with NIR laser irradiation can effectively increase temperature in cancer treatment. As shown in Supporting Information Figs. S19 and S20, after 24 h-post injection of FGP and FHP, the relative tumor growth curves of 4T1 tumor-bearing mice after various treatments for 14 d. (B) The average tumor weight in each treatment at 14 d. (C–E) H&E staining, Ki67 immunohistochemical staining and TUNEL analysis of tumor tissues after different treatments. (F) The number of nodules on the surface of lung excised from 4T1 tumor-bearing mice. (G) Representative H&E staining of lungs. Data are presented as mean ± SD (n = 6, **P < 0.01 FGP with NIR vs. other treatments).
infrared thermal images and temperature curves showed that the temperature was quickly increased and reached about 58.7°C, with no significance between the FHP and FGP groups, due to the equal concentration of FeS. In addition, the therapeutic efficacy of tumor inhibition of FGP was evaluated in 4T1 tumor-bearing mice. After the tumor reached a volume of approximately 100 mm³, the tumor-bearing mice were divided to six groups, including saline, FHP, and FGP with or without NIR laser irradiation. The relative tumor volumes presented in Fig. 7A demonstrated that saline with NIR and FHP showed some degree cancer inhibition in the first days after treatment due to the increased temperature or Fenton reaction. However, thereafter tumors grew quickly and there was no significant different with the control group. In addition, due to the photothermal effect of FHP and starvation, and the Fenton reaction of FGP, mice in both two groups treated with FHP plus NIR and FGP showed an approximately 60% rate of tumor inhibition. However, the tumor growth in mice treated with FGP plus NIR was significantly suppressed and was almost eliminated. Tumor weight was consistent with the results of relative tumor volumes (Fig. 7B and Supporting Information Fig. S21). These results indicated that the combination therapy of FGP could effectively inhibit tumor growth due to the higher accumulation and deep penetration in vivo.

The therapeutic efficacy of different treatments was further evaluated by H&E staining and TUNEL assay. As shown in Fig. 7C, extensive cell damage was observed in the group treated with FGP plus NIR laser irradiation, consistent with the results of TUNEL staining (Fig. 7E). Nearly all tumor cells were dead following the synergistic therapy of FGP and NIR irradiation. In addition, immunohistochemical staining of tumor sections for Ki-67 antigen was employed to determine the extent of tumor cell proliferation (Fig. 7D). Visually, tumor cells in the FGP plus NIR group exhibited decreased Ki-67 expression indicating markedly reduced tumor cell proliferation and tumor metastasis after treatment. The number of pulmonary metastatic nodules was quantified to further evaluate the anti-metastasis efficacy after tumor treatment. As shown Fig. 7F, H&E staining of lung tissue slices revealed the pronounced presence of metastatic nodules in saline group, while lung metastasis was negligible in mice treated with FGP plus NIR irradiation. In addition, the groups treated with FHP plus NIR irradiation and FGP displayed a decreased number of metastatic nodules (Fig. 7G). The collective results indicated that the combination therapy of FGP could enhance antitumor efficacy and inhibit tumor metastasis.

3.7. Biosafety evaluation of FGP

Biological safety was evaluated according to the weight of mice after different treatments. There showed no significant difference between these groups, indicating that FGP had no obvious toxicity for mice (Supporting Information Fig. S22). Also, the major organs were harvested and stained with H&E. No distinct tissue damage was observed (Supporting Information Fig. S23). Given the prior demonstration that GOx in FGP catalyzed the reduction in level of glucose, the blood glucose was determined after intravenous injection of FGP. Compared with the saline group, the blood glucose was slightly decreased in the first few hours, and quickly recovered to the level of the saline group (Supporting Information Fig. S24). In addition, there were no obvious changes in the levels of AST, ALT, ALP and CREA in the FGP treated group, which indicated that FGP was safe for the liver and kidney (Supporting Information Figs. S25 and S26). The hematology marker of FGP treatment did not change on Days 1, 3 and 7 (Supporting Information Fig. S27). All these results demonstrated that the safety of FGP for cancer treatment in vivo.

3.8. In vivo CRT expression and DC maturation

Foregoing results proved that the combination therapy of FGP could boost the ICD of 4T1 cell in vitro. To verify whether the significant tumor inhibition benefited from an ICD induced...
immune effect, the ICD markers of CRT and HMGB-1 expression were also evaluated in vivo following various treatments of mice. As shown in Fig. 8A and B, bright fluorescence was observed in tumors treated with FHP and NIR irradiated compared with the control group, indicating that PTT could induce ICD of tumor cells. Of note, the synergistic therapy of FGP remarkably induced CRT translocation and HMGB-1 expression by nearly 3-fold compared to the observations following FHP plus NIR irradiation, highlighting that the increased ROS generation and photothermal effect of FGP could amplify ICD to provoke an antitumor immune response. Given the satisfactory ICD-induction of FGP, the maturation of DC (CD11c^+CD80^+CD86^+) in lymph nodes (LNs) was analyzed by flow cytometry after various treatments on Day 3. The percentage of matured DCs increased significantly in the FGP plus PTT group compared with saline group (48.7% vs. 4.88%). The increase was much higher than that in the saline plus NIR irradiation group (15.1%) and FHP plus NIR irradiation group (19.0%) group (Fig. 8C and D). These results indicated that the FGP treatment could efficiently promote DC maturation by boosting the ICD of tumor cells.

3.9. In vivo combination therapy of FGP and ICB immunotherapy

The demonstration that FGP could increase CRT expression to amplify ICD and promote DC maturation indicated that FGP
might induce tumor-specific immune response to attack cancer cells. We evaluated the immune therapeutic efficacy of the combination of FGP and CTLA-4 blockade therapy to destroy local tumors and eliminate distant metastatic tumors. As illustrated in Fig. 9A, each mouse was subcutaneously inoculated with two CT26 colorectal tumors on both flanks. The tumor in the left flank (the primary tumor) was treated by FGP with NIR laser irradiation. The distant tumor in right flank was designed as the model of abscopal tumor. Then, the mice were divided randomly into five groups, including: (1) Saline, (2) Saline + NIR+α-CTLA4, (3) FHP + NIR+α-CTLA4, (4) FGP+α-CTLA4, (5) FGP + NIR+α-CTLA4. After 24 h following intravenous injection, NIR laser irradiation (808 nm, 1.8 W/cm²) was performed only on the primary tumors. Afterward, CTLA4 blockade therapy was adopted three times by the intravenous injection of anti-CTLA4 at the dosage of 10 μg per mouse on Days 2, 5 and 8.

The tumor growth curves of the primary tumors and distant tumors were monitored every second day to assess the therapeutic effect. As expected, the FGP plus NIR group exhibited a near complete inhibition of primary tumor growth (Fig. 9B). Most notably, for tumors at the left side (distant tumor) without NIR treatment, the FGP + NIR group also induced the most pronounced tumor growth inhibition among all five groups (Fig. 9C). These results indicated that the combination therapy of FGP with CTLA4 blockade could enhance immunotherapy to inhibit distant metastatic tumors, due to the amplified ICD of FGP. It has been well-known that cytotoxic T lymphocytes (CTLs) play a positive role in cancer immunotherapy. To understand the mechanism underlying the inhibition of distant tumors after combination therapy, the CTLs were analyzed in the untreated distant tumors on Day 8 after the different treatments in primary tumor. As displayed in the flow cytometry analysis (Fig. 9D and E), the percentage of CTLs (CD3⁺CD8⁺) that could directly kill targeted tumor cells manifestly increased to 16.75% in the group treated with FGP plus NIR, which was 4.1 times higher than that of the saline group (4.16%). The levels of CD8⁺ T cells, Foxp3⁺ cells and IFN-γ in distant tumors were further analyzed by immuno-fluorescence staining (Fig. 9F). It was found the FGP and FHP plus NIR showed slightly fluorescence increased, while enhanced percentage of CD8⁺ T cells (Fig. 9G) and fluorescence intensity of IFN-γ (Fig. 9I) were observed in FGP plus NIR irradiation combined with α-CTLA4. These results may have reflected the strong immune activation of FGP treatment. It is well known that antitumor immunotherapy is suppressed by regulatory T cells (Treg, Foxp3⁺). The levels of Foxp3⁺-positive Treg cells decreased in distant tumors of FGP plus NIR irradiation and CTLA4 blockade groups (Fig. 9H). The collective results demonstrated that the amplified ICD induced by the synergistic therapy of FGP produced a strong anti-tumor immunotherapy to inhibit distant tumors.

4. Conclusions

In summary, a cascade bioreactor was successfully developed that involved the PTX induced self-assembly of FeS-GOx nanodots via hydrophobic interaction. Due to the mild biomineralization method, FGP maintained high enzymatic activity of GOx to consume glucose and generate H₂O₂, and thereby producing more •OH for CDT enhancement. Due to the acid tumor microenvironment, FGP could quickly disassemble to release ultrasmall FeS-GOx with enhanced tumor penetration in 3D tumor spheroids. With NIR laser irradiation, the photothermal effect induced a temperature increase that significantly promote GOx activity. In addition, the combination therapy of FGP could effectively kill tumor cells and increase CRT exposure in dying tumor cells to amplify ICD both in vitro and in vivo. The amplified ICD with CRT and HMGB-1 expression promoted antigen presentation and maturation of DCs to strengthen anti-tumor response. In combination with anti-CTLA4 blockade therapy, increased infiltration of CTLs was observed in distant tumors after treated with FGP bioreactor. The synergistic therapy of FGP could completely eliminate tumors and significantly suppress distant tumors with enhanced activation of anti-tumor immune response. Therefore, this work provides a promising strategy of the simply constructed and synergistic comprehensive cancer therapy, which can eliminate primary tumors and enhance the immune response for the inhibition of metastasis.

Acknowledgments

This work was financially supported by the Youth Foundation of Jiangsu province (No. BK20180699, China), National Natural Science Foundation of China (Nos. 81803439, and 81703940).

Author contributions

Hao Ren, Xueming Li and Jiahui Yong designed the research. Jiahui Yong carried out the experiments and performed data analysis. Qingqing Yang, Zhen Yang, Zhangya Liu, Yan Xu and Hao Wang participated part of the experiments. Hao Ren and Jiahui Yong wrote the manuscript. Xing Jiang, Hao Ren and Wenjun Miao revised the manuscript. All of the authors have read and approved the final manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supporting information

Supporting data to this article can be found online at [https://doi.org/10.1016/j.apscb.2021.05.005](https://doi.org/10.1016/j.apscb.2021.05.005).

References

1. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275–87.
2. Chao Y, Xu LG, Liang C, Feng LZ, Xu J, Dong ZL, et al. Combined local immunostimulatory radiosotope therapy and systemic immune checkpoint blockade imparts potent antitumor responses. Nat Biomed Eng 2018;2:611–21.
3. Auslander N, Zhang G, Lee JS, Frederick DT, Miao BC, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med 2018;24:1545–9.
4. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune check- point blockade. Nat Rev Immunol 2019;20:1–15.
5. Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11.
6. Lu JQ, Liu XS, Liao YP, Salazar F, Sun BB, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 2017;8:1–14.
7. Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. *Nat Med* 2016;22:624.

8. Wang L, Niu MY, Zheng CX, Zhao HJ, Niu XX, Li L, et al. A core–shell nanoplaton for synergistic enhanced sonodynamic therapy of hypoxic tumor via cascaded strategy. *Adv Healthc Mater* 2018;7:1800819.

9. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. *Nat Rev Cancer* 2012;12:860–75.

10. Li L, Li YC, Yang CH, Radford DC, Wang JW, Janát-Amsbury M, et al. Inhibition of immunosuppressive tumors by polymer-assisted inductions of immunogenic cell death and multivalent PD-L1 cross-linking. *Adv Funct Mater* 2020;30:1908961.

11. Yang WJ, Zhang FW, Deng HZ, Lin LS, Wang S, Kang F, et al. Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. *ACS Nano* 2019;14:620–31.

12. Lu Y, Yang YN, Gu ZY, Zhang J, Song H, Xiang GY, et al. Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and co-delivery platform for enhanced cancer immunotherapy. *Biomaterials* 2018;175:82–92.

13. Gan SJ, Tong XN, Zhang Y, Wu JH, Yu YQ, Yuan Ah. Covalent organic framework-supported molecularly dispersed near-infrared dyes boost immunogenic phototherapy against tumors. *Adv Funct Mater* 2019;29:1902757.

14. He YC, Cong C, He YQ, Hao ZN, Li CH, Wang S, et al. Tumor hypoxia relief overcomes multidrug resistance and immune inhibition for self-enhanced photodynamic therapy. *Chem Eng J* 2019;375:122070.

15. Liu T, Liu WL, Zhang MK, Yu WY, Gao F, Li CX, et al. Ferrous-supply-regeneration nanoeengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. *ACS Nano* 2018;12:12181–92.

16. Shen ZY, Song JB, Yung BC, Zhou ZJ, Wu AG, Chen XY. Emerging strategies of cancer therapy based on ferroptosis. *Adv Mater* 2018;30:1704007.

17. Bao WE, Liu XW, Lv YL, Lu GH, Li F, Zhang F, et al. Nanolongan with multiple on-demand conversions for ferroptosis–apoptosis combined anticancer therapy. *ACS Nano* 2019;13:260–73.

18. Yang YN, Tang J, Abbaraju PL, Jambhulkar M, Song H, Zhang M, et al. Hybrid nanoreactors: enabling an off-the-shelf strategy for concurrently enhanced chemo-immunotherapy. *Angew Chem Int Ed* 2018;130:11938–45.

19. Chang F, Li F, Lu GH, Nie WD, Zhang LJ, Lv YL, et al. Engineering magnetosomes for ferroptosis/immunosuppression synergism in cancer. *ACS Nano* 2019;13:5662–73.

20. Li B, Hao GY, Sun B, Gu Z, Xu ZP. Engineering a therapy-induced "immunogenic cancer cell death" amplifier to boost systemic tumor elimination. *Adv Funct Mater* 2020;30:1909745.

21. Bokare AD, Choi W. Review of iron-free Fenton-like systems for activating H$_2$O$_2$ in advanced oxidation processes. *J Hazard Mater* 2014;275:121–35.

22. Wang TT, Zhang H, Liu HH, Yuan Q, Ren F, Han YB, et al. Boosting H$_2$O$_2$-guided chemodynamic therapy of cancer by enhancing reaction kinetics through versatile biomimetic Fenton nanocatalysts and the second near-infrared light irradiation. *Adv Funct Mater* 2020;30:1906128.

23. Wang M, Wang DM, Chen Q, Li CX, Li ZQ, Lin J. Recent advances in glucose-oxidase-based nanocomposites for tumor therapy. *Small* 2019;15:1903895.

24. Li J, Burgess DJ. Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. *Acta Pharm Sin B* 2020;11:2110–24.

25. Feng W, Han XG, Wang RY, Gao X, Hu P, Yue WW, et al. Nanocatalysts-augmented and photothermal-enhanced tumor-specific sequential nanocatalytic therapy in both NIR-I and NIR-II bio-windows. *Adv Mater* 2019;31:1805919.

26. Zhang YF, Yang YC, Jiang SS, Li F, Lin J, Wang TF, et al. Degradable silver-based nanoplaton for synergetic cancer starving-like/metal ion therapy. *Mater Horizons* 2019;6:169–75.

27. Fu LH, Qi C, Hu YR, Lin J, Huang P. Glucose oxidase-instructed multimodal synergistic cancer therapy. *Adv Mater* 2019;31:1808325.

28. Zhang R, Feng LZ, Dong ZL, Wang L, Liang C, Chen JW, et al. Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. *Biomaterials* 2018;162:123–31.

29. Chen XH, Li YX, Li SW, Gao M, Ren L, Tang BZ. Mitochondria-and lysosomes-targeted synergistic chemo-photodynamic therapy associated with self-monitoring by dual light-up fluorescence. *Adv Funct Mater* 2018;28:1804362.

30. Wang YQ, Liu ZY, Wang H, Meng ZJ, Wang YL, Miao WJ, et al. Starvation-amplified CO generation for enhanced cancer therapy via an erythrocyte membrane-biometric gas nanofactory. *Acta Biomater* 2019;92:241–53.

31. Xie W, Deng WW, Zan MH, Rao L, Yu GT, Zhu DM, et al. Cancer cell membrane camouflaged nanoparticles to realize starvation therapy together with checkpoint blockades for enhancing cancer therapy. *ACS Nano* 2019;13:2849–57.

32. Zhang M, Wang WT, Wu F, Zheng T, Ashley J, Mohammadniai M, et al. Biodegradable poly (γ-glutamic acid)-glucose oxidase@carbon dot nanoparticles for simultaneous multimodal imaging and synergetic cancer therapy. *Biomaterials* 2020;252:121016.

33. Zhang YH, Qiu WX, Zhang M, Zhang L, Zhang XZ. MnO$_2$ nanor: motor: a prospective cancer-starving therapy promoter. *ACS Appl Mater Interfaces* 2018;10:15030–9.

34. Yang X, Yang Y, Gao F, Wei JJ, Qian CG, Sun MJ. Biomimetic hybrid nanozymes with self-supplied H$^+$ and accelerated O$_2$ generation for enhanced starvation and photodynamic therapy against hypoxic tumors. *Nano Lett* 2019;19:4334–42.

35. Lu ZJ, Gao JY, Fang C, Zhou Y, Li X, Han GR. Porous Pt nanospheres incorporated with GOx to enable synergistic oxygen-inductive starvation/electrodynamic tumor therapy. *Adv Sci* 2020;7:2001223.

36. Sun YX, Zhao DY, Wang G, Wang Y, Cao LL, Sun J, et al. Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development. *Acta Pharm Sin B* 2020;8:1382–96.

37. Nam J, Son SJ, Ochyl LJ, Kauri A, Schwendeman A, Moon JJ. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. *Nat Commun* 2018;9:1–13.

38. Chen Q, Xu LG, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjunct nanoparticles together with checkpoint blockade for effective cancer immunotherapy. *Nat Commun* 2016;7:1–13.

39. Zhou ZG, Zhang BL, Wang SS, Zai WJ, Yuan AH, Hu YQ, et al. Perfluorocarbon nanoparticles mediated platelet blocking disrupt vascular barriers to improve the efficacy of oxygen-sensitive antimtumor drugs. *Small* 2018;14:1801694.

40. Liang X, Ye XY, Wang C, Xing CY, Miao QW, Xie ZJ, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. *J Control Release* 2019;296:150–61.

41. Hu JJ, Liu MD, Gao F, Chen Y, Peng SY, Li ZH, et al. Photo-controlled liquid metal nanoparticle-enzyme for starvation/photothermal therapy of tumor by win-win cooperation. *Biomaterials* 2019;217:119303.

42. Tang ZM, Zhang HL, Liu YY, Ni DL, Zhang H, Zhang JW, et al. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplaton for self-enhanced tumor imaging and therapy. *Adv Mater* 2017;29:1701683.

43. Yang WT, Xiang CY, Xu Y, Chen SZ, Zeng WW, Liu K, et al. Albumin-constrained large-scale synthesis of renal clearable ferrous sulfide quantum dots for T1-Weighted MR imaging and photo-theranostics of tumors. *Biomaterials* 2020;255:120186.

44. Yang WT, Shi XD, Shi YY, Yao DF, Chen SZ, Zhou X, et al. Beyond the roles in biomimetic chemistry: an insight into the intrinsic catalytic activity of an enzyme for tumor-selective phototheranostics. *ACS Nano* 2018;12:12169–80.

45. Jin QT, Liu JJ, Zha WJ, Dong ZL, Liu Z, Cheng L. Albumin-assisted synthesis of ultrasmall Fe$_2$O$_3$ nanodots for imaging-guided photothermal enhanced photodynamic therapy. *ACS Appl Mater Interfaces* 2018;10:332–40.
46. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583–92.

47. Peng JR, Yang Q, Xiao Y, Shi K, Liu QY, Hao Y, et al. Tumor microenvironment responsive drug-dye-peptide nanoassembly for enhanced tumor-targeting, penetration, and photo-chemo-immuno-therapy. Adv Funct Mater 2019;29:1900004.

48. Yu WQ, Liu R, Zhou Y, Gao HL. Size-tunable strategies for a tumor targeted drug delivery system. ACS Cent Sci 2020;6:100–16.

49. Zhou ZW, Liu YD, Zhang MH, Li CZ, Yang RX, Li J, et al. Size switchable nanoclusters fueled by extracellular ATP for promoting deep penetration and MRI-guided tumor photothermal therapy. Adv Funct Mater 2019;29:1904144.

50. An L, Yan CG, Mu XL, Tao C, Tian QW, Lin JM, et al. Paclitaxel-induced ultrasmall gallic acid-Fe@BSA self-assembly with enhanced MRI performance and tumor accumulation for cancer theranostics. ACS Appl Mater Interfaces 2018;10:28483–93.

51. Xie CK, Cen D, Ren ZH, Wang YF, Wu YJ, Li X, et al. FeS@BSA nanoclusters to enable H2S-amplified ROS-based therapy with MRI guidance. Adv Sci 2020;7:1903512.

52. Chen Q, Chen JW, Liang C, Feng LZ, Dong ZL, Song XJ, et al. Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Control Release 2017;263:79–89.

53. Yu SG, Chen ZW, Zeng XA, Chen XS, Gu Z. Advances in nanomedicine for cancer starvation therapy. Theranostics 2019;9:8026.

54. Gao SS, Lin H, Zhang HX, Yao HL, Chen Y, Shi J. Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv Sci 2019;6:1801733.

55. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54–61.

56. Zhang ZW, Wang H, Tan T, Li J, Wang ZW, Li YP. Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis. Adv Funct Mater 2018;28:1801840.

57. Song WT, Shen LM, Wang Y, Liu Q, Goodwin TJ, Li JJ, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 2018;9:1–11.